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We describe the clinical characteristics and outcomes 
of adults hospitalized with pneumonia during the pandemic 
(H1N1) 2009 outbreak. Patients admitted to a general hos-
pital in San Luis Potosí, Mexico, from April 10 through May 
11, 2009, suspected to have inﬂ  uenza  virus–associated 
pneumonia were evaluated. We identiﬁ  ed 50 patients with 
suspected inﬂ  uenza pneumonia; the presence of inﬂ  uen-
za virus was conﬁ  rmed in 18: 11 with pandemic (H1N1) 
2009 virus, 5 with unsubtypeable inﬂ  uenza A virus, 1 with 
seasonal inﬂ  uenza A virus (H3N2), and 1 in whom assay 
results for seasonal and pandemic (H1N1) viruses were 
positive. Eighteen patients were treated in the intensive 
care unit, and 10 died. During the pandemic (H1N1) 2009 
outbreak, severe pneumonia developed in young adults 
who had no identiﬁ  able risk factors; early diagnosis and 
treatment of inﬂ  uenza virus infections may have a determi-
nant role in outcome.
A 
novel inﬂ   uenza A virus, pandemic (H1N1) 2009 
virus, has been identiﬁ  ed as the cause of an epidemic 
outbreak of respiratory illness throughout the world (1). 
Current information indicates that the pandemic (H1N1) 
2009 virus has been circulating in Mexico since at least 
March 2009 and that it has been the cause of an increase 
in the number of hospitalizations of young adults since 
April 2009 (1). The city of San Luis Potosí played a major 
role in raising awareness of the presence of an unusual 
and nonsubtypeable inﬂ  uenza A virus during the early 
days of the outbreak (2).
The Hospital Central “Dr. Ignacio Morones Prieto” is 
a public hospital located in San Luis Potosí that served as 
a reference center for evaluation and treatment of patients 
with suspected inﬂ  uenza virus pneumonia. In this article, 
we describe the results of investigations performed to de-
termine the etiology of this outbreak and report the clinical 
ﬁ  ndings, treatments, and patient outcomes.
Patients and Methods
Study Site
The city of San Luis Potosí is located in central Mexi-
co and is the capital of the state of San Luis Potosí (3). The 
state population was 2,410,414 in 2005; the population of 
the San Luis Potosí metropolitan area in the same year was 
957,753 (4). The Hospital Central provides medical ser-
vices to mid- and low-income populations from all areas of 
the state; it has 269 beds in total, 250 in adult and pediatric 
wards and 19 in the intensive care unit (ICU). 
Patients
Starting April 10, 2009, when the ﬁ  rst case of pan-
demic (H1N1) 2009 was identiﬁ  ed, all patients admitted 
to Hospital Central with lower respiratory tract infections 
(LRTIs) were screened for the presence of inﬂ  uenza virus. 
Patients who experienced acute onset of respiratory symp-
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toms (cough, rhinorrhea, and/or dyspnea) and fever were 
assessed for possible inﬂ  uenza-related pneumonia, includ-
ing radiologic evaluation. This report includes all adult 
patients with radiographic evidence of pneumonia admit-
ted during the ﬁ  rst month of the pandemic (H1N1) 2009 
outbreak.
Clinical, Laboratory, and Bacteriologic Information
Patients admitted to medical wards and the ICU were 
subjected to the hospital’s standard diagnostic protocol: 
blood cultures, HIV antibody testing, chest radiograph, lab-
oratory tests, and spontaneous or induced sputum samples 
for Gram staining and culture. These tests were performed 
at admission and every 48–72 hours thereafter. Patients re-
ceiving mechanical ventilation had samples for minibron-
choalveolar lavage (mini-BAL) (5), blood, and urine sent 
for bacterial cultures at admission and every 48–72 hours, 
or in the event of new or persistent fever. Bronchoscopy 
with BAL was performed as clinically indicated. A quan-
titative threshold of 105 CFU/mL for mini-BAL was used 
and of 104 CFU/mL for BAL (6). Patients were treated with 
at least the following standard antimicrobial drug regimens: 
those with criteria for acute lung injury (ALI, partial pres-
sure of oxygen in arterial blood [paO2]/fraction of inspired 
oxygen [FiO2] = 201–300) or acute respiratory distress syn-
drome (ARDS, paO2/FiO2<200) received ceftriaxone and/
or vancomycin plus levoﬂ  oxacin or clarithromycin, and 
patients treated in medical wards received levoﬂ  oxacin. 
Therapeutic decisions were individualized by the attending 
physician. Deceased patients for whom the family granted 
consent were subjected to postmortem examinations to re-
cover lung specimens for bacteriologic culture, inﬂ  uenza 
virus detection, and histopathologic analysis.
Sample Collection and Processing
Respiratory samples obtained from patients with sus-
pected inﬂ  uenza infection were placed in either normal sa-
line or viral transport media and kept refrigerated at 4ºC 
until their arrival at the laboratory. A 200-μL aliquot of 
these samples was used for RNA extraction, and the remain-
ing volume was stored at –70°C. Viral RNA was isolated 
using the High Pure Viral RNA Kit (Roche Diagnostics, 
Mannheim, Germany). Sample collection and processing 
were carried out according to national and international 
biosafety guidelines and recommendations (7,8).
Inﬂ  uenza Virus Detection
A multiplex reverse transcription–PCR (RT-PCR) 
capable of distinguishing type A from type B inﬂ  uenza vi-
rus was developed based on previously published primers 
(9). One-step RT-PCR was performed using the Access 
RT-PCR System (Promega Corporation, Madison, WI, 
USA) at 48ºC for 45 min, followed by 94°C for 2 min, 40 
cycles of 30 s at 94°C, 30 s at 56°C,  30 s at 72°C, and a 
ﬁ  nal step at 72ºC for 5 min. Inﬂ  uenza A samples were sub-
sequently subtyped using a multiplex PCR with sequence 
speciﬁ  c primers approach adapted from previous publica-
tions (Table 1) (11). PCR products were subjected to elec-
trophoresis on 1.5% agarose gels prestained with ethidium 
bromide at 6 volts/cm for 45 min and digitally documented. 
An RT-PCR for detection of pandemic (H1N1) 2009 vi-
rus was developed based on early sequencing data (EpiFlu 
Database, http://platform.gisaid.org). RT was carried out at 
38ºC for 45 min by using UniFlu-RT oligonucleotide; PCR 
involved the newly developed Sw-NS-F 5′-ATG-GAC-
TCC-AAC-ACC-3′ and Sw-NS-R 5′-TTA-AAT-AAG-
CTG-AAA-CGA-G-3′ oligonucleotides at 1.6 μmol/L ﬁ  nal 
concentration, 0.02 IU/μL of Taq (Vivantis Technologies 
Sdn Bhd Selangor D.E., Malaysia), 200 μmol/L deoxynu-
cleoside triphosates, and 1.5 mmol/L MgCl2. PCR program 
was 95ºC for 5 min, followed by 15 cycles of 95ºC for 20 
s, 54ºC for 30 s, and 72ºC for 1.5 min, and a ﬁ  nal step of 2 
min at 72ºC. One microliter of a 1:1 dilution of the ﬁ  rst PCR 
product was then used in a second PCR by using similar 
components except 1 mmol/L MgCl2 and 800 nmol/L ﬁ  nal 
concentration of internal oligonucleotides Sw1-F 5′-CTT-
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Table 1. Oligonucleotide primers used for the subtyping of type A influenza viruses, Mexico 
Oligonucleotide Sequence  (5ƍ ĺ 3ƍ) Amplicon,  bp  Reference 
UniFlu-RT AGC-AAA-AGC-AGG  Full  genomic  (10) 
HA1-F GAA-ATT-TGC-TAT-GGC-TGA-CGG-GR  This  study 
HA1-R GAC-ACT-ACA-GAG-ACA-TAA-GCA-TTT-TC 
171 
(11) 
HA3-F CAG-CAA-AGC-CTA-CAG-CAA-MTG-TT  This  study 
HA3-R GGC-ATA-GTC-ACG-TTC-AAT-GCT-G 
236 
(11) 
HA5-F AAA-CTC-CAA-TRG-GGG-CGA-TAA-AC  This  study 
HA5-R1 CAA-CGG-CCT-CAA-ACT-GAG-TGT  (11) 
HA5-R2 CCA-ACA-GCC-TCA-AAC-TGA-GTG-T 
344 
This study 
NA1Nw-F ACT-CAR-GAG-TCT-GAA-TGT-G 
NA1Nw-R1 GTC-CTT-CCT-ATC-CAA-ACA-CC 
NA1Nw-R2 GTT-CTC-CCG-AGC-CAG-ATA-CC 
409 This  study 
NA2-F1 GGA-AAA-TCG-TTC-ATA-CTA-GCA-MAT-TG  This  study 
NA2-F2 GGG-AAA-ATC-GTT-CAT-ATT-AGC-ACA-TTG  (11) 
N2-R1 AGC-ACA-CAT-AWC-TGG-AAA-CAA-TGC 
176 
This study Severe Pneumonia and Pandemic (H1N1) 2009, Mexico 
GAA-AGA-GGA-ATC-GAG-CG-3′ and Sw1-R 5′-GTC-
TCC-CAT-TCT-CAT-CAC-AGT-3′ (429-bp amplicon). 
Inﬂ  uenza virus detection at the Instituto de Diagnóstico y 
Referencia Epidemiológicos (InDRE) and the State Pub-
lic Health Laboratory used the real-time RT-PCR protocol 
developed by the US Centers for Disease Control and 
Prevention (CDC).
Virologic and Epidemiologic Data
To assess the presence of respiratory syncytial virus 
(RSV) and inﬂ  uenza in the community we reviewed the 
database at the Virology Laboratory Universidad Autóno-
ma de San Luis Potosí (UASLP) and recorded the weekly 
number of viral detections from January 2008 through May 
2009. In addition, the weekly number of acute respiratory 
infections (ARI) reported in the state of San Luis Potosí 
and the emergency department (ED) at the Hospital Central 
was recorded.
Statistical Analysis
We analyzed demographic and clinical characteristics 
using descriptive statistics. Means or medians were used 
for description of continuous variables according to data 
distribution; categorical variables were described with the 
use of percentages. Comparisons among patient groups 
were made to assess factors associated with severe infec-
tions. We compared categorical variables using the χ2 or 
Fisher exact test; continuous variables were compared by 
using the Student t test or Mann-Whitney U test, according 
to data distribution. A p value <0.05 was considered sig-
niﬁ  cant. Statistical analyses were performed with SPSS for 
Windows (version 14.0, SPSS Inc., Chicago, IL, USA).
Results
An ARI outbreak was recorded in San Luis Potosí dur-
ing April and May 2009. The most characteristic feature 
observed at the beginning of this outbreak was an increase 
in severe pneumonia cases requiring hospitalization of 
young adult patients. The Figure shows the epidemiologic 
curve of the weekly number of ARI cases reported to Servi-
cios de Salud en el Estado de San Luis Potosí (state public 
health services) from January 2008 through May 2009 and 
the weekly number of ARI-related consultations provided 
in the ED at Hospital Central. In addition, the percentage 
of samples that were positive for inﬂ  uenza and RSV during 
each week at the Virology Laboratory UASLP is presented. 
Pneumonia patients included in this report were admitted 
during epidemiologic weeks 14 through 18 at a time that 
maximal pandemic (H1N1) 2009 virus circulation was 
documented.
From April 10 through May 11, 2009, a total of 70 pa-
tients >18 years of age were admitted to the Hospital Cen-
tral with suspected LRTI. After review of clinical, radio-
logic, and laboratory data, suspected inﬂ  uenza virus–related 
pneumonia was diagnosed for 50 of those patients; other 
patients were determined to have cholangitis and ARDS 
(1 patient), congestive heart failure (2 patients), aspiration 
pneumonia (2 patients), asthma without evidence of pneu-
monia on chest radiograph (5 patients), and inﬂ  uenza-like 
syndrome without pneumonia (10 patients). Nine of the 20 
excluded patients were tested for inﬂ  uenza infection, and 
results were negative for 8; samples from 1 of the patients 
found to have inﬂ  uenza-like illness without radiographic 
evidence of pneumonia were positive for pandemic (H1N1) 
2009 virus.
The main demographic features of our group of 50 pa-
tients are summarized in Table 2. Only 1 patient had an un-
derlying pulmonary disorder. Obesity was the most frequent 
underlying disorder and was the only underlying disorder 
in 17 patients; 6 patients had morbid obesity (body mass in-
dex [BMI] >40). The most frequent symptoms patients had 
at hospital admission were fever (100%), headache (96%), 
cough (94%), and myalgias (94%). The predominant radio-
logic pattern on chest radiograph was consolidation, with 
multilobar and unilobar consolidation in 39 and 11 patients, 
respectively. Twenty-one patients had ill-deﬁ  ned interstitial 
opacities. Three patients had evidence of unilateral pleural 
effusion that affected ≈10% of the hemithorax. HIV testing 
was performed for 45 patients; all results were negative. 
Evidence of a systemic inﬂ  ammatory response and muscle 
involvement was observed commonly, manifested by el-
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 1, January 2010  29 
0
50
100
150
200
250
300
350
400
Week 4 8 12 16 20 24 28 32 36 40 44 48 52 3 7 11 15 19
20082009
A
R
I
,
 
n
o
.
100
50
0
R
S
V
 
o
r
 
i
n
f
l
u
e
n
z
a
,
 
%
 
Figure. Weekly number of acute respiratory infections (ARI) 
reported in the state of San Luis Potosí, Mexico (no. of cases × 
100, light blue area); weekly number of ARI visits at the emergency 
department of Hospital Central “Dr. Ignacio Morones Prieto” 
(dark blue area); and weekly percentage of samples positive for 
respiratory syncytial virus (RSV; orange area) or inﬂ  uenza  (red 
area), Virology Laboratory, Universidad Autónoma de San Luis 
Potosí, during January 2008 through May 2009.RESEARCH
evated levels of C-reactive protein, creatine phosphokinase 
(CPK), lactate dehydrogenase (LDH), and aspartate amin-
otransferase (AST).
Thirty patients were treated in medical wards, 12 of 
whom met criteria for ALI, none had extrapulmonary in-
volvement, and all were discharged to home. Two patients 
with ARDS were treated in the ER.
Eighteen patients were treated in the ICU (17 with 
ARDS and 1 with ALI). The median positive end expira-
tory pressure at admission was 16 cm H2O (range 14–20 
cm) and media FiO2 was 80% (range 50%–100%); the 
mean Sepsis-related Organ Failure Assessment (SOFA) 
score and Acute Physiology and Chronic Health Evalua-
tion (APACHE) II at admission were 9.44 (range 5–15) 
and 17 (range 8–32), respectively. Twelve patients had he-
modynamic instability that required vasoconstrictors and 6 
had arrhythmias, mainly supraventricular and ventricular 
extrasystoles. Acute renal failure developed in 7 patients 
(6 within 72 hours of admission); 6 of these 7 patients 
experienced hemodynamic instability, and 3 required he-
modialysis. Nine patients with evidence of cardiac failure 
underwent transthoracic echocardiography. The mean left 
ventricular ejection fraction was 54.6%; in 2 patients, it 
was reduced at 40%. Nosocomial pneumonia developed in 
8 patients in the ICU after a median of 9.5 days of mechani-
cal ventilation.
Forty-ﬁ  ve patients received antiviral treatment with 
oseltamivir. The time elapsed from onset of symptoms to 
the start of antiviral drug treatment ranged between 1 and 
14 days (median 6 days). Four patients that did not receive 
antiviral drugs were discharged. The only patient who did 
not receive antiviral drugs and died was the ﬁ  rst patient 
with pandemic (H1N1) 2009–associated pneumonia to be 
admitted to our hospital during this outbreak; he had severe 
pneumonia and ARDS and died in the ED.
All patients were treated with antimicrobial drugs. 
Levoﬂ  oxacin or clarithromycin was included as part of the 
antimicrobial drug treatment of 48 (96%) patients; the 2 
patients who did not receive 1 of these antimicrobial drugs 
recovered and were discharged to home. Sixteen patients 
received steroids as part of their treatment; steroid use was 
assessed by the attending physician. The median number 
of days from admission to start of steroid treatment was 2 
days (range 0–20 days). The effect of steroid use on patient 
outcome is difﬁ  cult to assess because this treatment was 
used more frequently in patients with more severe disease.
Postmortem open lung biopsies were performed on 5 
patients and a complete necropsy was performed for 1. The 
pathologic ﬁ  ndings were those of diffuse alveolar damage; 
additionally, some patients had hemophagocytosis and cap-
illary and arteriolar thrombosis as well as enlargement of 
alveolar cells. One patient had acute bacterial pneumonia.
Respiratory samples from 45 patients were available 
for viral detection. Samples from 37 patients were tested 
at UASLP, while samples from 41 patients were tested at 
InDRE in Mexico City or the State Public Health Labora-
tory in San Luis Potosí using the real time RT-PCR pro-
tocol developed by CDC. Overall, inﬂ   uenza virus was 
detected in respiratory secretions of 15 (33.3%) of the 45 
patients who had respiratory samples available for testing; 
pandemic (H1N1) 2009 virus was detected for 10 patients, 
seasonal inﬂ  uenza A virus was detected for 4, and results of 
assays for pandemic (H1N1) 2009 and seasonal inﬂ  uenza 
A viruses were positive for 1 patient. Subtyping of samples 
positive for seasonal inﬂ  uenza virus showed that 1 infec-
tion was caused by inﬂ  uenza A (H1N1) virus (this ﬁ  nding 
corresponded to the patient with positive results for both 
seasonal and pandemic [H1N1] 2009 virus; due to the po-
tential for cross-reactivity, infection with pandemic [H1N1] 
2009 virus only cannot be ruled out in this patient) and 1 by 
inﬂ  uenza A (H3N2); the other 3 samples were not subtype-
able by our RT-PCR. In addition, RT-PCR was performed 
in lung tissue from 6 patients who died; the presence of in-
ﬂ  uenza virus was detected in 3 of these patients (pandemic 
[H1N1] 2009 virus in 1 and unsubtypeable inﬂ  uenza virus 
in 2). Detection of inﬂ  uenza virus in respiratory samples 
from these deceased patients was either negative (in 2 pa-
tients) or not possible because no respiratory sample was 
collected before the patient’s death (1 patient).
The duration of symptoms at the time of sample col-
lection for samples that tested positive for inﬂ  uenza virus at 
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Table 2. Demographic features of 50 adult patients admitted with 
acute pneumonia during the pandemic (H1N1) 2009  outbreak, 
San Luis Potosí, Mexico* 
Characteristic Value
Age, y, mean (SD, range)  38.4 (13.9, 21–69) 
Gender  
 M  29  (58) 
  F   21 (42) 
Residence
  San Luis Potosí municipality  30 (60) 
 Other  municipality  20  (40) 
No. home contacts, median (range)  4 (1–16) 
Presence of >1 underlying condition  30 (60) 
  Obesity (BMI > 30)  25 (55.6)† 
  Diabetes mellitus  8 (16) 
  Other conditions‡  9 (18) 
Smoker 13 (26)
Arrival at the hospital
 Directly  40  (80) 
  Referred from other hospital or clinic  10 (20) 
Influenza vaccination during previous 
winter season 
5 (10) 
*Values are no. (%) unless otherwise indicated. BMI, body mass index.  
†BMI data available only for 45 patients. 
‡Some patients had >1 additional underlying condition, including chronic 
renal failure (3), underlying heart disorder (3), systemic lupus 
erythematosus (1), chronic obstructive lung disease (1), hyperthyroidism 
(1), seizure disorder (1), and pregnancy (1). Severe Pneumonia and Pandemic (H1N1) 2009, Mexico 
UASLP was signiﬁ  cantly shorter (mean of 4.7 days) com-
pared with those samples that tested negative (8.8 days; p = 
0.02). Duration of symptoms at the time of sample collec-
tion was also demonstrated to be statistically signiﬁ  cant for 
samples that tested positive with the use of CDC’s real time 
RT-PCR protocol (mean 5.7 days) compared with those that 
were negative by this method (mean 9.5 days; p = 0.006).
We compared the demographic and clinical characteris-
tics of patients with pandemic (H1N1) 2009 infections and 
those that were negative on viral testing (Table 3). The clini-
cal presentation of both groups of patients was similar.
Sputum cultures obtained at time of admission were 
positive in 4 patients treated in medical wards; bacteria 
isolated included Staphylococcus aureus (2 patients) and 
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Table 3. Demographic, clinical, and laboratory features on admission of patients with pandemic (H1N1) 2009 and nonconfirmed 
influenza pneumonia cases during the pandemic (H1N1) 2009 outbreak, San Luis Potosí, Mexico* 
Characteristic
Pandemic (H1N1) 2009 
(n = 11) 
Nonconfirmed influenza
(n = 32)  p value 
Demographic features 
  Male sex   5 (45.5)  20 (62.5)  0.48
  Age, y, mean (SD)  34 (10.97)  39.47 (14)  0.25
  Resident of San Luis Potosí municipality   5 (45.5)  20 (62.5)  0.73
Clinical features 
    Presence of underlying conditions 
    Obesity (BMI >30)†     4 (40)  16 (57.1)  0.47
  Diabetes  2  (18.2)  4  (12.5)  0.64
    Other conditions‡  3 (27.3)  4 (12.5)  0.35
  Days from symptom onset to admission, mean (SD)  5.36 (2.5)  6.72 (3.13)  0.2
  Duration of symptoms at the onset of dyspnea, d, mean (SD)  2.73 (1.19)  3.91 (1.92)  0.06
  Pneumonia severity index (PORT score)  2.82 (1.47)  2.81 (1.15)  0.99
Symptoms 
  Fever   11 (100)  32 (100.0)  NA
  Headache   10 (90.9)  31 (96.9)  0.45
  Cough  11 (100)  31 (96.9)  1
  Myalgias  9 (81.8)  32 (100.0)  0.06
  Arthralgias  10 (90.9)  30 (93.8)  1
  Dyspnea  11 (100)  25 (78.1)  0.16
  Rhinorrea  8 (72.7)  25 (78.1)  0.69
  Malaise  6 (54.5)  11 (34.4)  0.29
  Blood-streaked sputum  3 (27.3)  13 (40.6)  0.49
  Diarrhea  1 (9.1)  7 (21.9)  0.66
  Pleuritic chest pain  1 (9.1)  5 (15.6)  1
  Vomiting  2 (18.2)  2 (6.3)  0.27
Physical examination findings on admission 
  BMI, mean (SD)  29.17 (6.48)  31.22 (5.4)  0.34
  Respiratory rate, bpm, mean (SD)  28.44 (4.91)  28.31 (7.24)  0.92
 Crackles  0.03
  Unilateral  4  (36.4)  2  (6.3) 
  Bilateral  7  (63.6)  30  (93.8) 
  Wheezing  5 (45.5)  18 (56.3)  0.73
Laboratory features 
  Total leukocyte count on admission (x 10
9/L), median (SD)  8.81 (6.1)  6.81 (4.13)  0.23
  Platelet count (x 10
9/L), mean (SD)§  173.6 (61.48)  227 (216.24)  0.45
  C-reactive protein, mg/dL, mean (SD)  14.51 (8.45)  18.74 (16.22)  0.41
  Creatinine, mg/dL, median (SD)  1.24 (0.87)  1.11 (0.75)  0.13
  Creatine phosphokinase, U/L, mean (SD) 376.78 (439.22)  462.2 (507.27)  0.65
  Lactate dehydrogenase, U/L, median (SD)§  952 (674.72)  1089.31 (602.32)  0.54
  AST, mg/dL, median (range)¶  43 (19–76)  69 (18–249)  0.07
  ALT, mg/dL, median (range)#  29 (13–55)  43 (13–177)  0.05
*Values are no. (%) unless otherwise indicated. BMI, body mass index; bpm, breaths per minute; PORT, Pneumonia Patient Outcomes Research Team 
(www.ahrq.gov/clinic/pneuclin.htm); NA, not available; AST, aspartate aminotransferase; ALT; alanine transaminase. 
†Data available for 38 patients. 
‡Includes chronic renal failure, systemic lupus erythematosus, pregnancy, cardiac disorder, seizure disorder. 
§Data available for 42 patients. 
¶Data available for 41 patients. 
#Data available for 40 patients.RESEARCH
Streptococcus pneumoniae (2 patients). For patients treated 
in the ICU all cultures performed on mini-BAL and BAL (1 
patient) at admission were negative; however, nosocomial 
pneumonia developed in 8 patients; microorganisms isolat-
ed included Acinetobacter baumanii (5 patients), S. aureus 
(1 patient), Escherichia coli (1 patient) and Candida sp. (1 
patient). BAL was performed for only 4 patients as part of 
evaluation of suspected nosocomial pneumonia. Six post-
mortem lung biopsy specimens were cultured; 1 showed 
growth of E. coli; the other 5 were negative.
Ten (20%) patients died; 8 were obese (BMI >30), and 
4 of those were morbidly obese (BMI >40). Eight patients 
died in the ICU with a median length of stay of 8.5 days 
(range 2–14 days), and 2 patients with ARDS died in the 
ED within hours after arrival. Six patients died within the 
ﬁ  rst 7 days following admission, and 4 died during the sec-
ond week after admission. In 5 patients, the cause of death 
was multiorgan dysfunction (pulmonary, cardiovascular, 
and renal); 3 deaths were attributed to severe ARDS refrac-
tory to ventilator management protocols (12); 1 was caused 
by mixed ARDS and shock refractory to vasoconstrictors; 
and 1 was caused by septicemia. The median length of stay 
for patients treated in the ICU was 13 days (range 2–60 
days); for those treated on the medical wards, this ﬁ  gure 
was 5 days (range 2–12 days).
The median duration of symptoms at time of admission 
for patients who died was longer (7.5 days) than for those 
who survived (5 days, p = 0.025); duration of symptoms be-
fore admission for patients who died in the ER was similar 
to duration of symptoms for patients who died in the ICU. 
The mean SOFA and APACHE II scores on admission for 
patients treated in the ICU who survived were 7.5 (range 
5–11) and 13 (range 8–18), respectively; in comparison, 
for patients who died the mean values of these scores were 
12 (range 10–15) and 21 (range 15–32), respectively. On 
the other hand, patients who received antiviral drug therapy 
during the ﬁ  rst 5 days after initiation of symptoms had a 
better outcome than those who did not (survival of 95% 
of patients vs. 70%, respectively; p = 0.037). However, 
sample size was not sufﬁ  cient to perform an appropriate 
multivariate analysis to deﬁ  ne the independent contribution 
of duration of illness, antiviral drug therapy, and other vari-
ables to patient outcome.
Discussion
Since pandemic (H1N1) 2009 was ﬁ  rst identiﬁ  ed in 
spring 2009, there has been a worldwide dissemination of 
this virus (1). Although the precise origin of this strain has 
not yet been determined, Mexico was the ﬁ  rst country to 
show the effects of the epidemic caused by this virus. In 
addition, more severe cases have been registered in our 
country, particularly in young adults, in comparison to the 
rest of the world.
Pneumonia is recognized as the most important com-
plication of inﬂ  uenza infections (13). LRTI in patients with 
inﬂ  uenza may be caused directly by viral invasion or result 
from bacterial complications (14,15). The occurrence of 
progressive disease, with bilateral pulmonary consolidation 
or ARDS, associated with high death rates has been de-
scribed for patients with inﬂ  uenza-associated pneumonia, 
particularly in those with infections caused by new sub-
types of inﬂ  uenza virus. In contrast, bacterial pneumonia 
complicating inﬂ  uenza usually occurs after near resolution 
of inﬂ  uenza symptoms (16,17). Our study cohort was com-
posed mostly of young adults without severe cardiovascu-
lar or pulmonary underlying disorders in whom the onset of 
dyspnea was, on average, 3.5 days after the onset of inﬂ  u-
enza symptoms. In only 4 (8%) of the 50 patients included 
in this report was there clear evidence of the participation 
of bacteria in the disease process; this number contrasts 
with previous reports of community-acquired pneumonia, 
for which bacteria are reported more frequently. Our results 
suggest that bacterial co-infection played a minor role as a 
cause of pneumonia in these patients. In addition, no histo-
pathologic evidence of bacterial pneumonia was observed 
in 5 of the 6 deceased patients on whom lung biopsies were 
performed. 
Although we were not able to conﬁ  rm  pandemic 
(H1N1) 2009 virus in all patients, several factors support 
the notion that a high proportion of their infections were 
caused by this virus. These factors include the clustering 
of cases of severe pneumonia in young adults (>85% of 
the patients became ill during a 2-week period) coincident 
with the identiﬁ  cation of a novel inﬂ  uenza virus shown to 
be circulating in the community.
A striking feature observed in this cohort of patients 
was the high frequency of systemic involvement with 
laboratory evidence of myositis/rhabdomyolysis, elevated 
acute-phase reactants, ARDS, hemodynamic instability, 
and acute renal failure. Elevation of LDH levels has been 
reported for patients with seasonal inﬂ  uenza but has not 
been considered a speciﬁ  c marker of severity. Elevation of 
CPK levels was frequently observed in patients treated at 
our hospital, and elevation of CPK and AST levels sug-
gest that muscle inﬂ  ammation was present in these patients. 
Myositis (with or without rhabdomyolysis) has been asso-
ciated previously to inﬂ  uenza infections (18–21). Of note, 
elevated CPK levels were observed in patients with and 
without conﬁ  rmed inﬂ  uenza virus infections.
Why these severe manifestations of inﬂ  uenza infections 
occurred in young adult patients during this outbreak re-
mains an unanswered question. Although almost two thirds 
of patients hospitalized with pneumonia at our institution 
had underlying health disorders, the presence of chronic re-
spiratory or cardiovascular diseases were rare. Obesity was 
the most frequent underlying disorder and was present in 
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more than half of the patients; in contrast, the prevalence of 
obesity for adults >20 years of age in San Luis Potosí was 
31.3% in 2006 (22). Eight of 10 patients who died were 
obese, including 4 who were morbidly obese. Obesity has 
been suggested to be a proinﬂ  ammatory chronic condition 
and thus may have contributed to some of the manifestations 
observed in these patients (23,24). The presence of obesity 
as a possible risk factor for severe pandemic (H1N1) 2009 
has been noted previously. In a report from Michigan, 9 of 
10 patients with pandemic (H1N1) 2009 infection requiring 
intensive care were obese (25). However, larger studies are 
needed to determine the role of obesity as a risk factor for 
severe inﬂ  uenza pneumonia.
There are several limitations to our study. First, only 
pneumonia patients were included. Therefore, the effect of 
inﬂ  uenza as a cause of hospitalizations is probably under-
estimated because patients with exacerbations of chronic 
obstructive pulmonary disease and asthma, as well as with 
congestive heart failure decompensation triggered by in-
ﬂ  uenza, may have been excluded. Second, we did not have 
appropriate respiratory samples from all patients admitted 
with pneumonia because some patients were admitted be-
fore the existence of an outbreak had been identiﬁ  ed. In 
addition, patients with more severe infections tended to 
have a longer duration of illness at the time of admission, 
reducing the likelihood that inﬂ  uenza may have been de-
tected. Third, inﬂ  uenza infection could not be conﬁ  rmed 
in most patients, and other causes of acute pneumonia 
(such as other viruses) were not excluded. However, be-
cause the clinical manifestations were similar in all cases, 
patients became ill in a short period simultaneously with 
a sudden increase in ARI in San Luis Potosí, and pandem-
ic (H1N1) 2009 infections were detected at a time when 
RSV and seasonal inﬂ  uenza circulation had declined, we 
consider it is likely that many cases may have been caused 
by inﬂ  uenza virus.
During the pandemic (H1N1) 2009 outbreak in San 
Luis Potosí, Mexico, young adults without identiﬁ  able risk 
factors became ill with severe pneumonia. Until predictors 
of severe pandemic (H1N1) 2009 virus infections are iden-
tiﬁ  ed, early diagnosis and prompt antiviral treatment seem 
to be the best measures to avoid serious illness caused by 
this virus (26,27).
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